Clinical trial
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in…
NCT00248092 · New River Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00248092 |
|---|---|
| Title | Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse |
| Official title | A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse |
| Lead sponsor | New River Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders |
| Intervention type | Drug |
| Interventions | NRP104 |
| Enrollment | 36 |
| Start date | Jan 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Nov 3, 2005 |
| Last update posted | Nov 5, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: